aH5N1c — Competitive Intelligence Brief

aH5N1c (aH5N1c) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Infectious disease.

phase 3 Influenza vaccine Infectious disease Biologic

Target snapshot

aH5N1c (aH5N1c) — Seqirus. aH5N1c is a vaccine that stimulates the body's immune response to the H5N1 subtype of the influenza A virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
aH5N1c TARGET	aH5N1c	Seqirus	phase 3	Influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine
Fluarix Tetra Vaccine	Fluarix Tetra Vaccine	GlaxoSmithKline	marketed	Inactivated influenza vaccine
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

1. GlaxoSmithKline · 8 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Seqirus · 2 drugs in this class
4. MedImmune LLC · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. Novartis · 1 drug in this class
7. Protein Sciences Corporation · 1 drug in this class
8. ModernaTX, Inc. · 1 drug in this class
9. Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
10. Janssen Vaccines & Prevention B.V. · 1 drug in this class